An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non–small cell lung cancer via persistent activation of ERK signalling

Po Lin Lin, Tzu Chin Wu, De Wei Wu, Lee Wang, Chi Yi Chen, Huei Lee

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

High programmed cell death 1 ligand 1 (PD-L1) expression in tumour tissues was associated with poor outcomes in non–small cell lung cancer (NSCLC) due to evasion of tumour immune surveillance. However, the role of PD-L1 in tumour invasion and resistance to tyrosine kinase inhibitor (TKI) treatments is not fully understood. Here, we provide evidence to support the involvement of PD-L1 expression in the invasiveness and TKI resistance in NSCLC cells by increased Bcl-2-associated athanogene-1 (BAG-1) expression. The upregulation of BAG-1 transcription by PD-L1 was verified by constructing the BAG-1 promoters using the polymerase chain reaction (PCR) and deletion mutations for luciferase reporter assays. The results indicated that C/EBPβ phosphorylation by extracellular signal-regulated kinase (ERK) signalling was responsible for PD-L1-mediated BAG-1 transcription. Mechanistically, the PD-L1-induced BAG-1 expression reciprocally increased PD-L1 expression due to persistent activation of ERK signalling, and it consequently conferred TKI resistance in NSCLC cells. The mechanistic action of this cell model was further confirmed by an animal model, affirming that PD-L1 conferred tumour invasiveness and TKI resistance via persistent activation of ERK signalling by the PD-L1/BAG-1 axis. We therefore suggest a combination of an ERK inhibitor with a TKI as a potential strategy for conquering PD-L1-mediated tumour invasion and TKI resistance in NSCLC patients whose tumours harbour high PD-L1/high BAG-1 expression.

Original languageEnglish
Pages (from-to)95-105
Number of pages11
JournalEuropean Journal of Cancer
Volume85
DOIs
Publication statusPublished - Nov 1 2017

Fingerprint

CD274 Antigen
Extracellular Signal-Regulated MAP Kinases
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Neoplasms
Tumor Escape
Sequence Deletion

Keywords

  • BAG-1
  • BIM
  • EGFR
  • NSCLC
  • PD-L1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non–small cell lung cancer via persistent activation of ERK signalling. / Lin, Po Lin; Wu, Tzu Chin; Wu, De Wei; Wang, Lee; Chen, Chi Yi; Lee, Huei.

In: European Journal of Cancer, Vol. 85, 01.11.2017, p. 95-105.

Research output: Contribution to journalArticle

@article{8cf4ab2869704403910cdf1d29d19d0c,
title = "An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non–small cell lung cancer via persistent activation of ERK signalling",
abstract = "High programmed cell death 1 ligand 1 (PD-L1) expression in tumour tissues was associated with poor outcomes in non–small cell lung cancer (NSCLC) due to evasion of tumour immune surveillance. However, the role of PD-L1 in tumour invasion and resistance to tyrosine kinase inhibitor (TKI) treatments is not fully understood. Here, we provide evidence to support the involvement of PD-L1 expression in the invasiveness and TKI resistance in NSCLC cells by increased Bcl-2-associated athanogene-1 (BAG-1) expression. The upregulation of BAG-1 transcription by PD-L1 was verified by constructing the BAG-1 promoters using the polymerase chain reaction (PCR) and deletion mutations for luciferase reporter assays. The results indicated that C/EBPβ phosphorylation by extracellular signal-regulated kinase (ERK) signalling was responsible for PD-L1-mediated BAG-1 transcription. Mechanistically, the PD-L1-induced BAG-1 expression reciprocally increased PD-L1 expression due to persistent activation of ERK signalling, and it consequently conferred TKI resistance in NSCLC cells. The mechanistic action of this cell model was further confirmed by an animal model, affirming that PD-L1 conferred tumour invasiveness and TKI resistance via persistent activation of ERK signalling by the PD-L1/BAG-1 axis. We therefore suggest a combination of an ERK inhibitor with a TKI as a potential strategy for conquering PD-L1-mediated tumour invasion and TKI resistance in NSCLC patients whose tumours harbour high PD-L1/high BAG-1 expression.",
keywords = "BAG-1, BIM, EGFR, NSCLC, PD-L1",
author = "Lin, {Po Lin} and Wu, {Tzu Chin} and Wu, {De Wei} and Lee Wang and Chen, {Chi Yi} and Huei Lee",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.ejca.2017.07.025",
language = "English",
volume = "85",
pages = "95--105",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non–small cell lung cancer via persistent activation of ERK signalling

AU - Lin, Po Lin

AU - Wu, Tzu Chin

AU - Wu, De Wei

AU - Wang, Lee

AU - Chen, Chi Yi

AU - Lee, Huei

PY - 2017/11/1

Y1 - 2017/11/1

N2 - High programmed cell death 1 ligand 1 (PD-L1) expression in tumour tissues was associated with poor outcomes in non–small cell lung cancer (NSCLC) due to evasion of tumour immune surveillance. However, the role of PD-L1 in tumour invasion and resistance to tyrosine kinase inhibitor (TKI) treatments is not fully understood. Here, we provide evidence to support the involvement of PD-L1 expression in the invasiveness and TKI resistance in NSCLC cells by increased Bcl-2-associated athanogene-1 (BAG-1) expression. The upregulation of BAG-1 transcription by PD-L1 was verified by constructing the BAG-1 promoters using the polymerase chain reaction (PCR) and deletion mutations for luciferase reporter assays. The results indicated that C/EBPβ phosphorylation by extracellular signal-regulated kinase (ERK) signalling was responsible for PD-L1-mediated BAG-1 transcription. Mechanistically, the PD-L1-induced BAG-1 expression reciprocally increased PD-L1 expression due to persistent activation of ERK signalling, and it consequently conferred TKI resistance in NSCLC cells. The mechanistic action of this cell model was further confirmed by an animal model, affirming that PD-L1 conferred tumour invasiveness and TKI resistance via persistent activation of ERK signalling by the PD-L1/BAG-1 axis. We therefore suggest a combination of an ERK inhibitor with a TKI as a potential strategy for conquering PD-L1-mediated tumour invasion and TKI resistance in NSCLC patients whose tumours harbour high PD-L1/high BAG-1 expression.

AB - High programmed cell death 1 ligand 1 (PD-L1) expression in tumour tissues was associated with poor outcomes in non–small cell lung cancer (NSCLC) due to evasion of tumour immune surveillance. However, the role of PD-L1 in tumour invasion and resistance to tyrosine kinase inhibitor (TKI) treatments is not fully understood. Here, we provide evidence to support the involvement of PD-L1 expression in the invasiveness and TKI resistance in NSCLC cells by increased Bcl-2-associated athanogene-1 (BAG-1) expression. The upregulation of BAG-1 transcription by PD-L1 was verified by constructing the BAG-1 promoters using the polymerase chain reaction (PCR) and deletion mutations for luciferase reporter assays. The results indicated that C/EBPβ phosphorylation by extracellular signal-regulated kinase (ERK) signalling was responsible for PD-L1-mediated BAG-1 transcription. Mechanistically, the PD-L1-induced BAG-1 expression reciprocally increased PD-L1 expression due to persistent activation of ERK signalling, and it consequently conferred TKI resistance in NSCLC cells. The mechanistic action of this cell model was further confirmed by an animal model, affirming that PD-L1 conferred tumour invasiveness and TKI resistance via persistent activation of ERK signalling by the PD-L1/BAG-1 axis. We therefore suggest a combination of an ERK inhibitor with a TKI as a potential strategy for conquering PD-L1-mediated tumour invasion and TKI resistance in NSCLC patients whose tumours harbour high PD-L1/high BAG-1 expression.

KW - BAG-1

KW - BIM

KW - EGFR

KW - NSCLC

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=85028947297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028947297&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2017.07.025

DO - 10.1016/j.ejca.2017.07.025

M3 - Article

C2 - 28892778

AN - SCOPUS:85028947297

VL - 85

SP - 95

EP - 105

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -